The Manufacturers Life Insurance Company Lowers Stock Position in Humana Inc. (NYSE:HUM)

The Manufacturers Life Insurance Company cut its holdings in Humana Inc. (NYSE:HUM - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 108,944 shares of the insurance provider's stock after selling 4,999 shares during the quarter. The Manufacturers Life Insurance Company owned about 0.09% of Humana worth $27,640,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Dodge & Cox lifted its holdings in shares of Humana by 106.7% during the 4th quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock valued at $2,587,345,000 after acquiring an additional 5,264,045 shares in the last quarter. Vanguard Group Inc. increased its stake in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider's stock valued at $3,254,899,000 after buying an additional 1,751,857 shares during the period. Norges Bank acquired a new stake in shares of Humana in the 4th quarter valued at $416,202,000. Pzena Investment Management LLC lifted its holdings in shares of Humana by 44.0% during the fourth quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider's stock worth $915,736,000 after buying an additional 1,103,132 shares during the last quarter. Finally, Boston Partners lifted its position in Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider's stock worth $279,236,000 after purchasing an additional 893,637 shares during the period. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Humana Price Performance

HUM traded down $3.48 on Tuesday, reaching $253.21. The stock had a trading volume of 506,887 shares, compared to its average volume of 1,746,713. The company has a market capitalization of $30.56 billion, a price-to-earnings ratio of 25.47, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm has a 50-day moving average of $266.21 and a 200-day moving average of $270.69.

Humana (NYSE:HUM - Get Free Report) last issued its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The firm's revenue was up 8.4% compared to the same quarter last year. During the same quarter last year, the company earned $7.23 EPS. As a group, sell-side analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be paid a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a yield of 1.40%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio (DPR) is 25.04%.

Analyst Ratings Changes

HUM has been the subject of a number of research reports. Truist Financial increased their target price on Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research note on Friday, April 11th. Barclays raised their target price on shares of Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a research note on Friday, April 11th. Guggenheim initiated coverage on shares of Humana in a research note on Wednesday, April 9th. They issued a "buy" rating and a $326.00 price target on the stock. Oppenheimer increased their target price on Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Finally, Raymond James raised shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective on the stock in a research report on Thursday, May 1st. Eighteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $287.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.